{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:22:27Z","timestamp":1777396947297,"version":"3.51.4"},"reference-count":64,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2019,5,7]]},"DOI":"10.3233\/jad-181179","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T11:54:00Z","timestamp":1553255640000},"page":"91-109","source":"Crossref","is-referenced-by-count":47,"title":["Choroid Plexus Acts as Gatekeeper for TREM2, Abnormal Accumulation of ApoE, and Fibrillary Tau in Alzheimer\u2019s Disease and in Down Syndrome Dementia"],"prefix":"10.1177","volume":"69","author":[{"given":"Ruma","family":"Raha-Chowdhury","sequence":"first","affiliation":[{"name":"Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, Cambridge, UK"},{"name":"John van Geest Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Henderson","sequence":"additional","affiliation":[{"name":"John van Geest Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh Alexander","family":"Raha","sequence":"additional","affiliation":[{"name":"John van Geest Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Vuono","sequence":"additional","affiliation":[{"name":"John van Geest Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Bickerton","sequence":"additional","affiliation":[{"name":"Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Jones","sequence":"additional","affiliation":[{"name":"Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fincham","sequence":"additional","affiliation":[{"name":"Clinical Pathology, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieren","family":"Allinson","sequence":"additional","affiliation":[{"name":"Clinical Pathology, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Holland","sequence":"additional","affiliation":[{"name":"Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid H.","family":"Zaman","sequence":"additional","affiliation":[{"name":"Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, Cambridge, UK"},{"name":"Cambridgeshire and Peterborough Foundation NHS Trust, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-181179_ref1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2559.1988.tb02018.x","article-title":"Alzheimer\u2019s disease and Down\u2019s syndrome","volume":"13","author":"Mann","year":"1988","journal-title":"Histopathology"},{"key":"10.3233\/JAD-181179_ref2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1212\/WNL.35.7.957","article-title":"Alzheimer\u2019s disease in Down\u2019s syndrome: Clinicopathologic studies","volume":"35","author":"Wisniewski","year":"1985","journal-title":"Neurology"},{"key":"10.3233\/JAD-181179_ref3","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1056\/NEJM198906013202203","article-title":"Amyloid A4 protein and its precursor in Down\u2019s syndrome and Alzheimer\u2019s disease","volume":"320","author":"Rumble","year":"1989","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-181179_ref4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.arcmed.2012.10.012","article-title":"Role of tau protein in neuronal damage in Alzheimer\u2019s disease and Down syndrome","volume":"43","author":"Cardenas","year":"2012","journal-title":"Arch Med Res"},{"key":"10.3233\/JAD-181179_ref5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archneur.61.3.378","article-title":"Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function","volume":"61","author":"Bennett","year":"2004","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-181179_ref6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.3233\/JAD-181179_ref7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.jcbfm.9600419","article-title":"Transport pathways for clearance of human Alzheimer\u2019s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system","volume":"27","author":"Bell","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JAD-181179_ref8","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS beta-amyloid in Alzheimer\u2019s disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"10.3233\/JAD-181179_ref9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/alzrt187","article-title":"Evidence for impaired amyloid beta clearance in Alzheimer\u2019s disease","volume":"5","author":"Wildsmith","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-181179_ref10","doi-asserted-by":"crossref","first-page":"170276","DOI":"10.1155\/2012\/170276","article-title":"Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer\u2019s disease","volume":"2012","author":"Wilcock","year":"2012","journal-title":"Curr Gerontol Geriatr Res"},{"key":"10.3233\/JAD-181179_ref11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00401-011-0864-5","article-title":"Microglial pathology in Down syndrome","volume":"122","author":"Xue","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-181179_ref12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer\u2019s disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-181179_ref13","first-page":"1569","article-title":"TREM2 and neurodegenerative disease","volume":"369","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-181179_ref14","first-page":"1568","article-title":"TREM2 and neurodegenerative disease","volume":"369","author":"Jonsson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-181179_ref15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/JAD-160663","article-title":"Neuroprotective effect of TREM-2 in aging and Alzheimer\u2019s disease model","volume":"55","author":"Raha","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-181179_ref16","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1056\/NEJMcibr1503954","article-title":"TREM2 and risk of Alzheimer\u2019s disease\u2013friend or foe?","volume":"372","author":"Tanzi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-181179_ref17","doi-asserted-by":"crossref","first-page":"992","DOI":"10.15252\/emmm.201606370","article-title":"TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance","volume":"8","author":"Xiang","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-181179_ref18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3233\/JAD-170814","article-title":"Erythromyeloid-derived TREM2: A major determinant of Alzheimer\u2019s disease pathology in Down syndrome","volume":"61","author":"Raha-Chowdhury","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-181179_ref19","doi-asserted-by":"crossref","first-page":"26043","DOI":"10.1074\/jbc.M115.679043","article-title":"Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2)","volume":"290","author":"Atagi","year":"2015","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-181179_ref20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.3233\/JAD-181179_ref21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer\u2019s disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.3233\/JAD-181179_ref22","doi-asserted-by":"crossref","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","article-title":"Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance","volume":"3","author":"Castellano","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.3233\/JAD-181179_ref23","first-page":"482","article-title":"Ultrastructural studies in APP\/PS1 mice expressing human ApoE isoforms: Implications for Alzheimer\u2019s disease","volume":"5","author":"Dikranian","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"key":"10.3233\/JAD-181179_ref24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","article-title":"ApoE and Abeta in Alzheimer\u2019s disease: Accidental encounters or partners?","volume":"81","author":"Kanekiyo","year":"2014","journal-title":"Neuron"},{"key":"10.3233\/JAD-181179_ref25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","article-title":"TREM2 binds to apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-beta by microglia","volume":"91","author":"Yeh","year":"2016","journal-title":"Neuron"},{"key":"10.3233\/JAD-181179_ref26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/2051-5960-1-55","article-title":"The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer\u2019s disease","volume":"1","author":"Raha","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-181179_ref27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1186\/s12864-015-2159-z","article-title":"Gene expression and functional annotation of human choroid plexus epithelium failure in Alzheimer\u2019s disease","volume":"16","author":"Bergen","year":"2015","journal-title":"BMC Genomics"},{"key":"10.3233\/JAD-181179_ref28","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.drudis.2015.05.003","article-title":"Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders","volume":"20","author":"Demeestere","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.3233\/JAD-181179_ref29","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1523\/JNEUROSCI.0006-15.2015","article-title":"Amyloid beta oligomers disrupt blood-CSF barrier integrity by activating matrix metalloproteinases","volume":"35","author":"Brkic","year":"2015","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-181179_ref30","doi-asserted-by":"crossref","first-page":"9805","DOI":"10.1523\/JNEUROSCI.0967-12.2012","article-title":"Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases","volume":"32","author":"Vandenbroucke","year":"2012","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-181179_ref31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2017.01.009","article-title":"The Down syndrome brain in the presence and absence of fibrillar beta-amyloidosis","volume":"53","author":"Annus","year":"2017","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-181179_ref32","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","article-title":"The pattern of amyloid accumulation in the brains of adults with Down syndrome","volume":"12","author":"Annus","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-181179_ref33","doi-asserted-by":"crossref","first-page":"243ra286","DOI":"10.1126\/scitranslmed.3009093","article-title":"TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis","volume":"6","author":"Kleinberger","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.3233\/JAD-181179_ref34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/(SICI)1096-8628(19990820)88:4<344::AID-AJMG10>3.0.CO;2-1","article-title":"Apo E genotypes and risk of dementia in Down syndrome","volume":"88","author":"Rubinsztein","year":"1999","journal-title":"Am J Med Genet"},{"key":"10.3233\/JAD-181179_ref35","first-page":"E156","article-title":"Hepcidin and ferroportin participate in iron clearance from brain endothelium: Failure of this process leads to iron accumulation in Alzheimer\u2019s disease","volume":"88","author":"Raha","year":"2013","journal-title":"Am J Hematol"},{"key":"10.3233\/JAD-181179_ref36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev.ne.17.030194.002421","article-title":"Normal and abnormal biology of the beta-amyloid precursor protein","volume":"17","author":"Selkoe","year":"1994","journal-title":"Annu Rev Neurosci"},{"key":"10.3233\/JAD-181179_ref37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1192\/bjp.172.6.493","article-title":"Population-based study of the prevalence and presentation of dementia in adults with Down\u2019s syndrome","volume":"172","author":"Holland","year":"1998","journal-title":"Br J Psychiatry"},{"key":"10.3233\/JAD-181179_ref38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1567205012666151020114607","article-title":"Aging in Down syndrome and the development of Alzheimer\u2019s disease neuropathology","volume":"13","author":"Head","year":"2016","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-181179_ref39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1042\/bst0300552","article-title":"Amyloid-beta oligomers: Their production, toxicity and therapeutic inhibition","volume":"30","author":"Walsh","year":"2002","journal-title":"Biochem Soc Trans"},{"key":"10.3233\/JAD-181179_ref40","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1073\/pnas.89.16.7437","article-title":"Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4\/beta protein","volume":"89","author":"Knauer","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-181179_ref41","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.neuron.2009.11.013","article-title":"Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance","volume":"64","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.3233\/JAD-181179_ref42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/156720507780362254","article-title":"Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: A position paper","volume":"4","author":"Finch","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-181179_ref43","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1194\/jlr.R800069-JLR200","article-title":"Apolipoprotein E: Structure determines function, from atherosclerosis to Alzheimer\u2019s disease to AIDS","volume":"50","author":"Mahley","year":"2009","journal-title":"J Lipid Res"},{"key":"10.3233\/JAD-181179_ref44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1532-5415.2008.02113.x","article-title":"Mortality, dementia, and apolipoprotein E genotype in elderly white women in the United States","volume":"57","author":"Little","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-181179_ref45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","article-title":"Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation","volume":"3","author":"Lemere","year":"1996","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-181179_ref46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/hmg\/8.4.711","article-title":"Association of an extended haplotype in the tau gene with progressive supranuclear palsy","volume":"8","author":"Baker","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JAD-181179_ref47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neulet.2004.05.119","article-title":"The tau H2 haplotype is almost exclusively Caucasian in origin","volume":"369","author":"Evans","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-181179_ref48","doi-asserted-by":"crossref","first-page":"2890 e2891","DOI":"10.1016\/j.neurobiolaging.2013.06.005","article-title":"Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family","volume":"34","author":"Guerreiro","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-181179_ref49","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1097\/00001756-199412000-00044","article-title":"Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down\u2019s syndrome from dementia","volume":"5","author":"Royston","year":"1994","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-181179_ref50","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1046\/j.1471-4159.1997.69051995.x","article-title":"Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer\u2019s amyloid beta","volume":"69","author":"Martel","year":"1997","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-181179_ref51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1073\/pnas.82.1.203","article-title":"Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets","volume":"82","author":"Elshourbagy","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-181179_ref52","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1172\/JCI36663","article-title":"apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain","volume":"118","author":"Deane","year":"2008","journal-title":"J Clin Invest"},{"key":"10.3233\/JAD-181179_ref53","doi-asserted-by":"crossref","first-page":"e0188802","DOI":"10.1371\/journal.pone.0188802","article-title":"Increased levels of plasma total tau in adult Down syndrome","volume":"12","author":"Kasai","year":"2017","journal-title":"PLoS One"},{"key":"10.3233\/JAD-181179_ref54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","article-title":"Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: Pilot case-control studies including patients with Alzheimer\u2019s disease and Down syndrome","volume":"12","author":"Tatebe","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-181179_ref55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ana.410410220","article-title":"Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down\u2019s syndrome","volume":"41","author":"Tokuda","year":"1997","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-181179_ref56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrn.2016.7","article-title":"TREM2 variants: New keys to decipher Alzheimer disease pathogenesis","volume":"17","author":"Colonna","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-181179_ref57","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuropharm.2016.01.028","article-title":"TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice","volume":"105","author":"Jiang","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-181179_ref58","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ana.410170310","article-title":"Occurrence of neuropathological changes and dementia of Alzheimer\u2019s disease in Down\u2019s syndrome","volume":"17","author":"Wisniewski","year":"1985","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-181179_ref59","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jnen\/nlv030","article-title":"The choroid plexus in healthy and diseased brain","volume":"75","author":"Kaur","year":"2016","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-181179_ref60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrn3921","article-title":"Development and functions of the choroid plexus-cerebrospinal fluid system","volume":"16","author":"Lun","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-181179_ref61","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1523\/JNEUROSCI.3081-14.2015","article-title":"Spatially heterogeneous choroid plexus transcriptomes encode positional identity and contribute to regional CSF production","volume":"35","author":"Lun","year":"2015","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-181179_ref62","doi-asserted-by":"crossref","first-page":"D960","DOI":"10.2741\/A658","article-title":"Human MHC class III and IV genes and disease associations","volume":"6","author":"Gruen","year":"2001","journal-title":"Front Biosci"},{"key":"10.3233\/JAD-181179_ref63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/hmg\/ddl437","article-title":"The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease","volume":"16","author":"Kimura","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JAD-181179_ref64","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/j.1742-4658.2007.05717.x","article-title":"RCAN1-1L is overexpressed in neurons of Alzheimer\u2019s disease patients","volume":"274","author":"Harris","year":"2007","journal-title":"FEBS J"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-181179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:32Z","timestamp":1777370972000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-181179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":64,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-181179","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]}}}